关键词: 新辅助化疗, 局部晚期结肠癌

Abstract: 【Abstract】〓Objective〓To investigate the feasibility, safety, and efficacy of neo-adjuvant chemotherapy of XELOX (oxaliplatin and capecitabine) for the resectable locally advanced colon carcinoma. Methods〓From Jan. 2010 to Dec. 2014, 100 patients with resectable locally advanced colon carcinoma (T3/T4 or N+) were randomized into either perioperative chemotherapy and surgery (study group, n=50) or surgery followed by postoperative chemotherapy (control group, n=50). Perioperative chemotherapy consisted of two-four preoperative cycles of intravenous Oxaliplatin(130 mg/m2) on day 1, and oral capecitabine (1000 mg/m2) for two weeks (day 1 to day 14) every 21 days and four to six postoperative cycles of the same regimen. Results〓All the patients completed neo-adjuvant chemotherapy and no severe grade 3-4 toxicity happened. All the tumours were resected with no significant differences in postoperative morbidity between the study group and the control group. These two groups were comparable in clinical T stage and N stage, and when compared with control, neo-adjuvant chemotherapy resulted insignificant involvement in N stage (P<0.01) and TNM (P<0.01) and less positive node (P<0.01). With a median follow-up of four years, median survival was 46 months in the neo-adjuvant chemotherapy group compared with 26 months in the control group. 5-year DFS were 44.9% and 33.6% (P=0.041) and 5-year OS were 51.0% and 41.6% (P=0.33). Conclusion〓Neo-adjuvant chemotherapy with Oxaliplatin and Capecitabine improve survival without additional serious adverse events in the treatment of patients with resectable locally advanced colon carcinoma.

Key words: Locally advanced colon carcinoma, Neoadjuvant chemotherapy